Session Details

S026 Update in General Dermatology

Sat, Mar 20, 9:00 AM - 12:00 PM
3 CME Available Symposium

DESCRIPTION

This session will review the current state of knowledge, evaluation, and treatment of hidradenitis suppurativa, use of JAK inhibitors in inflammatory skin disease, cancer-directed immunotherapy reactions, morphea/sclerderma, lupus, dermatomyositis, and urticaria.

LEARNING OBJECTIVES

1.

Evaluate the latest advances in pathophysiology for hidradenitis suppurativa, cancer-associated immunotherapy reactions, morphea/scleroderma, cutaneous lupus erythematosus and dermatomyositis, and urticaria.

2.

Determine new approaches to use of JAK inhibitors in inflammatory skin diseaes.

3.

Review current treatments and new developments for hidradenitis suppurativa, cancer-associated immunotherapy reactions, morphea/scleroderma, cutaneous lupus erythematosus and dermatomyositis, and urticaria.

DIRECTOR

Victoria P. Werth, MD, FAAD

Victoria P. Werth, MD, FAAD

University of Pennsylvania

DISCLOSURES

Victoria P. Werth, MD, FAAD

AbbVie – Consultant (1099 relationship)(Fees); Almirall – Consultant (1099 relationship)(Honoraria); Alumis – Consultant (1099 relationship)(Honoraria); Amgen – Investigator(Grants/Research Funding); AnaptysBio – Consultant(Honoraria); Architect Therapeutics – Consultant (1099 relationship)(Fees); argenx – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Arionix – Consultant (1099 relationship)(Honoraria); Astra Zeneca – Investigator(Grants/Research Funding); AstraZeneca – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Data Safety Monitoring Board(Honoraria); Atticus Pharma, Inc. – Consultant (1099 relationship)(Honoraria); Biogen – Consultant(Honoraria), Investigator(Grants/Research Funding); BMS – Consultant(Honoraria); Boehringer Ingelheim – Consultant (1099 relationship)(Honoraria); Cabaletta Bio – Consultant (1099 relationship)(Honoraria); Celexor Bio – Consultant (1099 relationship)(Fees); CSL Behring – Consultant(Honoraria), Investigator(Grants/Research Funding); Cugene – Consultant(Honoraria); Daiichi Sanko – Consultant (1099 relationship)(Honoraria); Dianthus Therapeutics – Consultant (1099 relationship)(Honoraria); Duality Bio – Consultant (1099 relationship)(Fees); EMD Serono – Consultant(Honoraria), Investigator(Grants/Research Funding); First Tracks Biotherapeutics – Consultant (1099 relationship)(Honoraria); Gilead Sciences – Consultant(Honoraria), Investigator(Grants/Research Funding); GlaxoSmithKline – Consultant(Honoraria); Glycoera – Investigator(Grants/Research Funding); Horizon Pharma, Inc. – Investigator(Grants/Research Funding); Immunovant – Consultant (1099 relationship)(Honoraria); Innovaderm Research Inc. – Consultant (1099 relationship)(Honoraria); Janssen Pharmaceuticals, Inc – Consultant(Honoraria), Investigator(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – Consultant(Honoraria); Lilly ICOS LLC – Consultant(Honoraria); Lupus Foundation of America – Consultant(Honoraria); Merck & Co., Inc – Consultant(Honoraria); Novartis – Advisory Board(Honoraria); Nuvig Therapeutics – Consultant (1099 relationship)(Honoraria); Odyssey Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Priovant Therapeutics – Investigator(Grants/Research Funding); Prolium – Consultant (1099 relationship)(Honoraria); Regeneron Pharmaceuticals, Inc. – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Sanofi Aventis – Consultant(Honoraria); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria); UCB – Consultant(Honoraria); Valuence – Consultant (1099 relationship)(Honoraria); Vindico Medical Education – Speaker/Faculty Education(Honoraria);